KRAS and non-small cell lung carcinoma: Indeed, current clinical guidelines do not recommend testing for KRAS mutations in the resectable stages of NSCLC due to the lack of agreement regarding its implications on prognosis (https://www.iaslc.org; https://www.aiom.it (accessed on 10 February)) [21].